Barclays PLC Minerva Neurosciences, Inc. Transaction History
Barclays PLC
- $377 Billion
- Q3 2024
A detailed history of Barclays PLC transactions in Minerva Neurosciences, Inc. stock. As of the latest transaction made, Barclays PLC holds 3 shares of NERV stock, worth $6. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3
Previous 3
-0.0%
Holding current value
$6
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding NERV
# of Institutions
21Shares Held
2.12MCall Options Held
0Put Options Held
0-
Federated Hermes, Inc. Pittsburgh, PA1.35MShares$3.09 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA252KShares$577,2170.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny157KShares$359,9880.0% of portfolio
-
Ubs Oconnor LLC Chicago, IL107KShares$245,6160.02% of portfolio
-
Black Rock Inc. New York, NY72.7KShares$166,4120.0% of portfolio
About Minerva Neurosciences, Inc.
- Ticker NERV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 5,340,190
- Market Cap $12.2M
- Description
- Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein ...